, 2010). To elucidate if glucoevatromonoside presented virus-inactivating

activity, a virucidal assay was performed, where infectious particles of HSV-1 were put in contact with different concentrations of glucoevatromonoside prior to be titrated by a plaque reduction assay. This treatment was not able to inhibit HSV-1 replication, even at a concentration 80 times higher (10 μM) than its IC50 (0.13 μM). Therefore, the anti-HSV activity of this compound was not exerted directly on HSV-1 particles before they have entered into the cells confirming the findings previously described for other cardenolides (Hartley et al., 2006, Nagai et al., 1972 and Su et al., 2008). To explore the effects of glucoevatromonoside directly

on the host cells, a pretreatment assay was performed. This strategy has not shown to inhibit HSV-1 replication, suggesting that this compound did not present prophylactic effect in vitro. Next, EPZ5676 clinical trial HSV-1 and glucoevatromonoside were added to Vero cells simultaneously to investigate if it could interfere with the early stages of viral infection. This strategy has also not shown inhibit HSV replication suggesting that viral adsorption and penetration were not affected. To confirm these findings, viral attachment and penetration were individually investigated, and the results attested that glucoevatromonoside indeed did not affect these early stages, even when tested at 2 μM – 16 times higher than its IC50 (0.13 μM) – corroborating our results obtained during the selleckchem simultaneous treatment and those by other authors ( Dodson et al., 2007 and Su et al., 2008). Fig. 3 shows a summary of these results. In order to detect in which stages of HSV replication cycle the glucoevatromonoside could be acting, time-of-addition and removal assays

were performed. As shown in Fig. 4, the anti-HSV-1 activity of glucoevatromonoside was preserved when added up to Urease 12 h p.i. decreasing thereafter. Concordantly, when glucoevatromonoside was removed the activity significantly reduced up to12 h p.i. These data suggested that glucoevatromonoside should be added up to 12 h p.i. to affect the HSV replication. Since glucoevatromonoside inhibited HSV-1 at the first 12 h of its replication cycle, after viral attachment and penetration into the cells, the viral transcription was investigated through RT-PCR to determine if this process was impaired by this cardenolide affecting or not the HSV-1 gene expression. For the post-infection treatment, Vero cells were infected for 1 h, and then treated with glucoevatromonoside, acyclovir or a combination of both, during 6 and 12 h p.i. Fig. 5 shows the mRNA levels of UL54, UL52 and UL13 HSV genes, which are α, β and γ genes, respectively. The treatments with glucoevatromonoside (0.13 μM), acyclovir (5 μM) or a combination of both during 12 h p.i.